EP0057699A1 - 5,6-o-isoalkylidene ascorbic acid derivatives - Google Patents

5,6-o-isoalkylidene ascorbic acid derivatives

Info

Publication number
EP0057699A1
EP0057699A1 EP81902234A EP81902234A EP0057699A1 EP 0057699 A1 EP0057699 A1 EP 0057699A1 EP 81902234 A EP81902234 A EP 81902234A EP 81902234 A EP81902234 A EP 81902234A EP 0057699 A1 EP0057699 A1 EP 0057699A1
Authority
EP
European Patent Office
Prior art keywords
ascorbic acid
tumor
alkyl group
composition according
enediol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP81902234A
Other languages
German (de)
French (fr)
Other versions
EP0057699A4 (en
Inventor
Andrew Welebir
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.
Original Assignee
NATIONAL FOUNDATION FOR CANCER RESEARCH Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NATIONAL FOUNDATION FOR CANCER RESEARCH Inc filed Critical NATIONAL FOUNDATION FOR CANCER RESEARCH Inc
Publication of EP0057699A1 publication Critical patent/EP0057699A1/en
Publication of EP0057699A4 publication Critical patent/EP0057699A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid

Definitions

  • the present invention relates condensation products between enediol ketolactones and 2-haloethyl isocyanates and pharmaceutically acceptable salts thereof as antitumor agents and possible analgesic agents, and more particularly, to condensation products of 5,6-0-isoalkylidene ascorbic acid derivatives with 2-haloethyl isocyanates and pharmaceutically acceptable salts thereof as novel antitumor agents and possibly analgesic agents.
  • the invention also includes pharmaceutical compositions containing these compounds and methods of using them.
  • antitumor agents derived from ascorbic acid includes condensation products between underivatized ascorbic acid and strongly electrophilic conjugated aldehydes, such as glyoxal, methyl glyoxal, phenyl glyoxal, and a number of olefinic aldehydes, such as acrolein and crotonic, maleic, and fumaric aldehydes (Fodor, et al, U. S. Patent No. 4,238,500).
  • aldehydes such as glyoxal, methyl glyoxal, phenyl glyoxal
  • olefinic aldehydes such as acrolein and crotonic, maleic, and fumaric aldehydes
  • Ascorbic acid was originally intended as a carrier for methyl glyoxal, which was subsequently to be released in vivo as the active antitumor agent. Free ascorbic acid has also been proposed as a prophylactic treatment for bladder carcinoma (Schlegel, Ann. N.Y. Acad. Sci., 432 (1975) .
  • antitttmor agents presently employed in clinical use consist of either complex natural products, cytotoxic antibiotics, nitrosoureas, and other alkylating or mutagenic agents.
  • BCNU bis -(2 chloroethyl)-N-nitrosourea
  • BCNU bis -(2 chloroethyl)-N-nitrosourea
  • the immediate precursor of these metabolites viz. the 2-chloroethyl carbonium ion
  • the alkylating agent accounts for the mutagenicity and much of the toxicity associated with the use of BCNU and other nitrosoureas.
  • the second major product resulting from the hydrolysis of BCNU in vivo is 2-chloroethyl isocyanate, which may account for the.carcinostatic effectiveness of BCNU.
  • the carbamoylated products In vivo resulting from the reaction of 2-chloroethyl isocyanate with a number of enzymes may be the possible mode of action.
  • the study of possible "carriers" of 2-chloroethyl isocyanate may, therefore, result in an antitumor agent of practica utility which would not involve the release of a mutagenic alkylating agent.
  • R is an alkyl group containing no nucleophilic substituents, e.g., such as amino, hydroxyl, or sulfhydryl groups but may comprise lower alkyl ethers, lower alkyl esters, or carbonate esters or carboxylic acids or amides, preferably ketal or acetals of the formula:
  • R 2 and R 3 are lower alkyl groups containing 1 to 3 carbons or H, preferably a protected ascorbic acid derivative which may be a 5,6-0-isoalkylidene ascorbic acid derivative, and more preferably the 5,6-0-isopropylidene derivative of ascorbic acid:
  • Ha1. is an electron-withdrawing group, such as a halogen, preferably C1, Br, or I, and more preferably C1.
  • the preferred solvents for the reaction are any solvent in which the final products show solubility with dipolor, aprotic solvents being preferred, such as lower aliphatic ketones, e.g., acetone, DMSO (dimethyl sulfoxide), DMF (dimethyl formamide), and HMPA (hexamethyl phosphoramide), along with other similar solven acetone being most preferred.
  • aprotic solvents such as lower aliphatic ketones, e.g., acetone, DMSO (dimethyl sulfoxide), DMF (dimethyl formamide), and HMPA (hexamethyl phosphoramide), along with other similar solven acetone being most preferred.
  • Reactants (1 part 5,6-0-isoalkylidene ascorbic acid to 2 to 10 parts of isocyanate, preferably 3 to 6 parts isocyanate) are combined in a small amount of solvent (1 part reactants to 1 to 100 parts of solvent) and reflexed under anlydrous conditions, preferably under an inert atmosphere, such as nitrogen or argon. While a large amount of material reacts within a 3 hour period, longer reaction times (up to 72 hours) depending on the solvent, are preferred. Reaction temperatures may range from less than 0° to 150°C, with 30° to 100°C being preferred.
  • the produ does not contain two carbamate linkages, and may, in fact, be a tricyclic compound in the case of the reaction between 5,6-0-isopropylidene ascorbic acid and 2-chloroethyl isocyanate (Scorbethane).
  • an object of the present invention to provide novel compounds having antitumor activity in humans and mammals. It is another object of the invention to provide condensation products of enediol ketolactones, notable ascorbic acid derivatives with the nucleophilic 5,6-0-positions protected by suitable protecting groups, and 2-haloethyl isocyanates having antitumor activity. Still another object of the invention is to provide novel effective antitumor agents at low dosages without the in vivo formation of mutagenic alkylating agents.
  • Yet another object of this invention is to provide novel compounds having analgesic activity.
  • Ascorbic acid was converted to the 5,6-0-isopropylidene ascorbic acid derivative employing the method of Solomon(Experie tia 19: 619 (1963)).
  • a 10g quantity of L-ascorbic acid (0.054 mol) was added to 100 ml of anhydrous acetone and cooled on an ice bath.
  • Anhydrous HCl was passed through the suspension with vigorous stirring for 0.5 hr.
  • Hexane (80ml) was added and the mixture was stirred and allowed to settle. The liquid was decan ed, and the solid was washed repeatedly with 100 ml volumes of acetone :hexane, 4:7, until all the HCl was removed.
  • the remaining solid (11.3g, 91%) had a MP of 220° (lit. 222°) and it pres ence was confirmed by IR and NMR.
  • Other 5 , 6 - 0 - isoalkyliden ascorbic acids may be synthes ized us ing this procedure .
  • Scorbethane the 2-chloroethyl isocyanate adduct of isopropylidene ascorbic acid, was prepared by suspending 2.16g (0.01 mol) of the isopropylidene derivative in 10 ml of anhydrous ace tone, and the reaction vessel was flooded with nitrogen. 2- chloroethyl isocyanate (4.4g, 0.04 mol) was added and the mixture was refluxed for 65 hours. The solvent was removed in vacuo an the compound was dried in vacuo for 48 hours over KOH. NMR analysis showed a singlet (6H) at 1.3 ppm, a multiplet (9H) at 3.7 ppm, and a multiplet (4H) at 4.1 ppm. IR showed peaks at
  • Antitumor screening data were obtained through the National Cancer Institute, Drug Evaluation Branch, National Institutes of Health, Bethesda, Maryland.
  • L-1210 lymphoid leukemia tumors (10 cells) were implanted in CDF 1 mice in accordance with NIH Protocols.
  • the results reported in Tables 1 and 2 are single dose responses with survival being evaluated five days after i.p. injection of Scorbethane (six days after implantation).
  • the compound was injected as a suspension in 10% EtOH, 10% emulphor, and 80% saline.
  • Log kill data indicates the number of tumor cells killed, and 30 -day survivors are termed "cured".
  • the degree of antitumor activity is expressed as a ratio of treated animals over control animals using NCI test evaluation numbers, as specified in individual protocols.
  • Table I shows the remarkable effectiveness of Scorbethane, the adduct found from the reaction of 5,6-0-isopropylidine ascorbic acid and 2-chloroethyl isopropylidene ascorbic acid and 2-chloroethyl isocyanate, against L-1210 lymphocytic leukemia, with results comparable to those observed from MeCCNU.
  • MeCCNU (1-cyclohexyl-3-(2-chloroethyl)-3-nitrosourea) is currently the most effective against L-1210 leukemia and many solid tumor systems.
  • T/C 184% at 47 mg/kg for L-1210), which has been widely studied in these tumor systems in the art.
  • Table II shows the effectiveness of Scorbethane vs. the P-1534 leukemia model. This model shows a higher degree of resistance to nitrosoureas than many other leukemia models. Again, activty approximates the activity of MeCCNU, exceeding that of BNCU, without in vivo production of an alkylating species.
  • nitrosoureas of the invention can be formulated into a form suitable for administration by methods well known in the art.
  • they can be admixed with pharmaceutically acceptable carriers or diluents such as ethanol, lactose, starch, magnesium stearate, tragacanth, gelatin and sodium carboxymethylcellulose, and the resulting mixture or solution may be processed by conventional procedures to pharmaceutical dosage unit forms such as capsules, tablets, powders, pills, ampoules, suppositories and the like.
  • the compounds of the invention may be administered orally or parenterally.
  • the drug may be given intravenously by first dissolving the compound to be administered in 0.5-10 ml of ethanol and adding 50-90% water thereto. Further dilution may be made with physiological saline solution or 5% dextrose (USP) with or without the inclusion of an emulsifying agent. Intravenous administration may be continued for a period of up to several hours.
  • 5 ,6-0-substituted ascorbic acid derivatives and similar compounds can be injected intravenously at dosages of about 0.1-10 mg/kg.
  • parenteral routes of administration may be accomplished using any formulation known in the art that allows for the emulsification, dissolution or suspension of relatively water-insoluble drugs or other compounds prior to parenteral administration.
  • the compounds When given in unit dosage forms orally, the compounds are active when provided in a gelatin capsule or tablet combined with pharmaceutically acceptable binders, fillers or other additives as known in the art.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Nouveaux produits de condensation entre des cetolactones d'enediol tel que de l'acide 5,6-0-isopropylidene ascorbique et des isocyanates de 2-chloroethyle presentant une puissante activite anti-tumorale probablement sans la liberation d'agents d'alkylation in vivo. Bien que les structures des produits ne puissent pas etre facilement tirees au clair, il apparait que leur activite est superieure a celle du BCNU (bis(2-chloroethyle)-N-nitrosouree) et parallele a celle de la nitrosouree NeCCNU(1-(4-trans-methylcyclohexyle)-3-(2-chlorotethyle)-3-nitrosouree), qui est toxique et tres efficace. Les composes preferes sont des produits de condensation selon la formule (FORMULE) ou R2 et R3 representent un groupe alkyle inferieur contenant de 1 a 3 atomes de carbone ou H et hal-CH2-CH2-N=C=O (B) ou hal represente I, Br ou Cl.New condensation products between enediol cetolactones such as 5,6-0-isopropylidene ascorbic acid and 2-chloroethyl isocyanates showing potent anti-tumor activity probably without the release of alkylating agents in vivo . Although the structures of the products cannot be easily clarified, it appears that their activity is superior to that of BCNU (bis (2-chloroethyl) -N-nitrosourea) and parallel to that of nitrosourea NeCCNU (1- ( 4-trans-methylcyclohexyle) -3- (2-chlorotethyle) -3-nitrosouree), which is toxic and very effective. The preferred compounds are condensation products according to the formula (FORMULA) where R2 and R3 represent a lower alkyl group containing from 1 to 3 carbon atoms or H and hal-CH2-CH2-N = C = O (B) or hal represents I, Br or Cl.

Description

DESCRIPTION TITLE
5,6-0-ISOALKYLIDENE ASCORBIC ACID DERIVATIVES
RELATED APPLICATIONS This application is a continuation-in-part of U. S. Serial No. 117,940 filed 14 August 1980.
TECHNICAL FIELD
The present invention relates condensation products between enediol ketolactones and 2-haloethyl isocyanates and pharmaceutically acceptable salts thereof as antitumor agents and possible analgesic agents, and more particularly, to condensation products of 5,6-0-isoalkylidene ascorbic acid derivatives with 2-haloethyl isocyanates and pharmaceutically acceptable salts thereof as novel antitumor agents and possibly analgesic agents. The invention also includes pharmaceutical compositions containing these compounds and methods of using them.
BACKGROUND ART
A number of ascorbic acid derivatives have been cited as having antiscorbutic activity and improved lipid solubility (Warnat, et al, U. S. Patent No. 2,150,140, Edwin, et al, U. S. Patent No. 2,454,749, Kobayashi, et al, U. S. Patent No. 3,318, 914, Hoseney, et al, U. S. Patent No. 4,044,154, Weisblatt, U. S. Patent No. 2,454,747), however, all appear to involve more or less selective esterification of one or more hydroxyl groups on the molecule. Japanese Patent No. 4,815,605 to Chitose Seiyaku Co., Ltd. reveals the preparation of certain phoshate salts from isopropylidene ascorbic acid, however, no reference is found as to the biological activity of the salts described therein. Furthermore, no reference can be found to any 5,6-0-isoalkylidene ascorbic acid derivative which shows antitumor or analgesic activity.
The only reference found to antitumor agents derived from ascorbic acid by the present inventor includes condensation products between underivatized ascorbic acid and strongly electrophilic conjugated aldehydes, such as glyoxal, methyl glyoxal, phenyl glyoxal, and a number of olefinic aldehydes, such as acrolein and crotonic, maleic, and fumaric aldehydes (Fodor, et al, U. S. Patent No. 4,238,500). A number of possible complex structures for the biologically active compound or compounds were originally described in the patent literature, and more specific structures were eventually proposed. Ascorbic acid was originally intended as a carrier for methyl glyoxal, which was subsequently to be released in vivo as the active antitumor agent. Free ascorbic acid has also been proposed as a prophylactic treatment for bladder carcinoma (Schlegel, Ann. N.Y. Acad. Sci., 432 (1975) .
Many highly effective antitttmor agents presently employed in clinical use consist of either complex natural products, cytotoxic antibiotics, nitrosoureas, and other alkylating or mutagenic agents.
One such compound in clinical use, BCNU (bis -(2 chloroethyl)-N-nitrosourea) has been shown to be metabolized into numerous products in vivo, such as 2-chloroethanol, vinyl chloride, acetaldehyde, and dichloroethane from the nitrosated side of the molecule (T. P. Johnston et al, J. Med. Chem. , 18: 654 (1975)). The immediate precursor of these metabolites, viz. the 2-chloroethyl carbonium ion, is a powerful alkylating agent and is known to effectively alkylate DNA within one hour after i.v. administration (O. J. Reed, et al, Cancer Res. 55: 568 (1975)). The alkylating agent accounts for the mutagenicity and much of the toxicity associated with the use of BCNU and other nitrosoureas.
The second major product resulting from the hydrolysis of BCNU in vivo is 2-chloroethyl isocyanate, which may account for the.carcinostatic effectiveness of BCNU. The carbamoylated products In vivo resulting from the reaction of 2-chloroethyl isocyanate with a number of enzymes may be the possible mode of action. The study of possible "carriers" of 2-chloroethyl isocyanate may, therefore, result in an antitumor agent of practica utility which would not involve the release of a mutagenic alkylating agent.
DISCLOSURE OF THE INVENTION In a search for such a "carrier", the present inventor has discovered, surprisingly, that reacting 2-chlorσethyl isocynate with an enediol ketolactone, more particularly, a 5,6-0-isoalky lϊdene ascorbic acid, produces an addition product or products, not readily identifiable, which possess potent antitumor activit more so than BCNU, and with less toxicity. The potent antitumor activity, furthermore, is exhibited to a much greater degree than other compounds derived from ascorbic acid in the prior art (Fodor, et al, U. S. Patent No. 4,238,500), possibly because the mammalian system is accustomed to metabolizing excesses of the released methyl glyoxal produced by the compounds of the prior art. 2-Chloroethyl isocyanate and its derivatives are not readily metabolized.
It has further been found by the instant inventor that adducts found with underivatiz.ed ascorbic acid and 2-chloroethyl isocyanates are inactive antitumor agents, thus necessitating blockage of the 5,6-0-positions of the molecule before the addition reaction is allowed to take place. Since this portion of the molecule may not be responsible for the antitumor effect, and since blockage of the 5,6-0-nucleophilic position is essential for synthesis, a variety of enediol ketolactones may be expected to exhibit activity.
According to the requirements of the present invention for a process which affords a product possessing potent antitumor activity, compounds of the following formulae are reacted. The enediol ketolactone A is reacted with the 2-haloisocyanate B to form the product:
wherein: R is an alkyl group containing no nucleophilic substituents, e.g., such as amino, hydroxyl, or sulfhydryl groups but may comprise lower alkyl ethers, lower alkyl esters, or carbonate esters or carboxylic acids or amides, preferably ketal or acetals of the formula:
wherein: R2 and R3 are lower alkyl groups containing 1 to 3 carbons or H, preferably a protected ascorbic acid derivative which may be a 5,6-0-isoalkylidene ascorbic acid derivative, and more preferably the 5,6-0-isopropylidene derivative of ascorbic acid:
B is preferably 2-chloroethyl isocyanate (R4=R5=H), however 2-chloroethyl isocyanates containing alkyl substituents are useful. Ha1. is an electron-withdrawing group, such as a halogen, preferably C1, Br, or I, and more preferably C1. The inclusion of other substituents which are known in the art to enhance water or lipid solubility, or pharmaceutically acceptable salts, are not beyond the scope of the present invention.
The preferred solvents for the reaction are any solvent in which the final products show solubility with dipolor, aprotic solvents being preferred, such as lower aliphatic ketones, e.g., acetone, DMSO (dimethyl sulfoxide), DMF (dimethyl formamide), and HMPA (hexamethyl phosphoramide), along with other similar solven acetone being most preferred.
Reactants (1 part 5,6-0-isoalkylidene ascorbic acid to 2 to 10 parts of isocyanate, preferably 3 to 6 parts isocyanate) are combined in a small amount of solvent (1 part reactants to 1 to 100 parts of solvent) and reflexed under anlydrous conditions, preferably under an inert atmosphere, such as nitrogen or argon. While a large amount of material reacts within a 3 hour period, longer reaction times (up to 72 hours) depending on the solvent, are preferred. Reaction temperatures may range from less than 0° to 150°C, with 30° to 100°C being preferred.
When the reaction is completed, excess solvent and isocyanat are removed by distillation or evaporation, preferably under vacuum to leave the product as an oily to crystalline solid. This is used directly after combining with an acceptable pharmaceutical carrier in the inhibition of tumor growth in mammalian and human systems.
While the structure of the compounds of the present invention is not readily elucidated, it is hypothesized that the produ does not contain two carbamate linkages, and may, in fact, be a tricyclic compound in the case of the reaction between 5,6-0-isopropylidene ascorbic acid and 2-chloroethyl isocyanate (Scorbethane). OBJECTS
It is, therefore, an object of the present invention to provide novel compounds having antitumor activity in humans and mammals. It is another object of the invention to provide condensation products of enediol ketolactones, notable ascorbic acid derivatives with the nucleophilic 5,6-0-positions protected by suitable protecting groups, and 2-haloethyl isocyanates having antitumor activity. Still another object of the invention is to provide novel effective antitumor agents at low dosages without the in vivo formation of mutagenic alkylating agents.
Yet another object of this invention is to provide novel compounds having analgesic activity.
BEST MODE OF THE INVENTION
Melting points were determined using a Thomas-Hoover capillary melting point apparatus and are uncorrected. Infrared (IR) spectra were obtained using a Perkin Elmer 397 spectrophotometer and NMR spectra were taken on a Nicolet 200 MHz instrument using CDCl3 as the solvent and TMS as an internal standard.
EXAMPLE 1
Ascorbic acid was converted to the 5,6-0-isopropylidene ascorbic acid derivative employing the method of Solomon(Experie tia 19: 619 (1963)). A 10g quantity of L-ascorbic acid (0.054 mol) was added to 100 ml of anhydrous acetone and cooled on an ice bath. Anhydrous HCl was passed through the suspension with vigorous stirring for 0.5 hr. Hexane (80ml) was added and the mixture was stirred and allowed to settle. The liquid was decan ed, and the solid was washed repeatedly with 100 ml volumes of acetone :hexane, 4:7, until all the HCl was removed. The remaining solid (11.3g, 91%) had a MP of 220° (lit. 222°) and it pres ence was confirmed by IR and NMR. Other 5 , 6 - 0 - isoalkyliden ascorbic acids may be synthes ized us ing this procedure .
Scorbethane condensation products of :
EXAMPLE 2
Scorbethane, the 2-chloroethyl isocyanate adduct of isopropylidene ascorbic acid, was prepared by suspending 2.16g (0.01 mol) of the isopropylidene derivative in 10 ml of anhydrous ace tone, and the reaction vessel was flooded with nitrogen. 2- chloroethyl isocyanate (4.4g, 0.04 mol) was added and the mixture was refluxed for 65 hours. The solvent was removed in vacuo an the compound was dried in vacuo for 48 hours over KOH. NMR analysis showed a singlet (6H) at 1.3 ppm, a multiplet (9H) at 3.7 ppm, and a multiplet (4H) at 4.1 ppm. IR showed peaks at
3250 cm-1 (N-H) , 1790 cm-1 (C=O) , (1680 cm-1 (amide II band), and 1540 cm-1 (N-C=O) , apparently residual or partially released isocyanate. Other enediol ketolactones undergo an identical reaction.
ANTITUMOR SCREENING
Antitumor screening data were obtained through the National Cancer Institute, Drug Evaluation Branch, National Institutes of Health, Bethesda, Maryland.
L-1210 lymphoid leukemia tumors, (10 cells) were implanted in CDF1 mice in accordance with NIH Protocols. The results reported in Tables 1 and 2 are single dose responses with survival being evaluated five days after i.p. injection of Scorbethane (six days after implantation). The compound was injected as a suspension in 10% EtOH, 10% emulphor, and 80% saline. Log kill data indicates the number of tumor cells killed, and 30 -day survivors are termed "cured". The degree of antitumor activity is expressed as a ratio of treated animals over control animals using NCI test evaluation numbers, as specified in individual protocols.
Table I shows the remarkable effectiveness of Scorbethane, the adduct found from the reaction of 5,6-0-isopropylidine ascorbic acid and 2-chloroethyl isopropylidene ascorbic acid and 2-chloroethyl isocyanate, against L-1210 lymphocytic leukemia, with results comparable to those observed from MeCCNU. MeCCNU (1-cyclohexyl-3-(2-chloroethyl)-3-nitrosourea) is currently the most effective against L-1210 leukemia and many solid tumor systems. Furthermore, the data show significant superiority over the results observed using BCNU (T/C = 184% at 47 mg/kg for L-1210), which has been widely studied in these tumor systems in the art.
> w r-* ra
Table II shows the effectiveness of Scorbethane vs. the P-1534 leukemia model. This model shows a higher degree of resistance to nitrosoureas than many other leukemia models. Again, activty approximates the activity of MeCCNU, exceeding that of BNCU, without in vivo production of an alkylating species.
Similar clinical results can be obtained with the use of the other compounds of the invention.
The nitrosoureas of the invention can be formulated into a form suitable for administration by methods well known in the art. For example, they can be admixed with pharmaceutically acceptable carriers or diluents such as ethanol, lactose, starch, magnesium stearate, tragacanth, gelatin and sodium carboxymethylcellulose, and the resulting mixture or solution may be processed by conventional procedures to pharmaceutical dosage unit forms such as capsules, tablets, powders, pills, ampoules, suppositories and the like.
The compounds of the invention, such as Scorbethane, may be administered orally or parenterally. For example, the drug may be given intravenously by first dissolving the compound to be administered in 0.5-10 ml of ethanol and adding 50-90% water thereto. Further dilution may be made with physiological saline solution or 5% dextrose (USP) with or without the inclusion of an emulsifying agent. Intravenous administration may be continued for a period of up to several hours.
5 ,6-0-substituted ascorbic acid derivatives and similar compounds can be injected intravenously at dosages of about 0.1-10 mg/kg.
Other parenteral routes of administration may be accomplished using any formulation known in the art that allows for the emulsification, dissolution or suspension of relatively water-insoluble drugs or other compounds prior to parenteral administration.
When given in unit dosage forms orally, the compounds are active when provided in a gelatin capsule or tablet combined with pharmaceutically acceptable binders, fillers or other additives as known in the art.
The invention being thus described, it will be obvious that the same may be varied in many ways. Such variations are not to be regarded as a departure from the spirit and scope of the invention, and all such modifications are intended to be included within the scope of the following claims.

Claims

WHAT IS CLAIMED IS:
1. A chemical composition comprising the addition products obtained through the reaction of an enediol ketolactone of the formula:
with a 2-chloroethyl isocyanate of the formula
wherein: hal is I, Br or CI,
R1 is hydrogen, an alkyl group, a substituted alkyl group which does not contain nucleophilic substituents or a ketal or acetal of the formula:
wherein:
R2 and R3 are each a lower alkyl group containing 1 to 3 carbon atoms or H, R4 and R5 , which may be the same or different, are each a lower alkyl group containing 1 to 3 carbon atoms or H.
2. A composition according to claim 1, wherein the enediol ketolactone is a 5 ,6-0-isoalkylidene ascorbic acid.
3. A composition according to claim 1, wherein R4 and R5 are H or a lower aliphatic side chain of one to three carbon atoms or a combination of these.
4. A composition according to claim 1, wherein the enediol ketolactone is 5,6-0-isopropylidene ascorbic acid and the isocyanate is 2-chloroethyl isocyanate.
5. A composition according to claim 1, wherein said reaction which forms said addition products is carried out in a dipolar aprotic solvent.
6. A composition according to claim 5, wherein said solvent is a lower aliphatic ketone.
7. A method for treating mammalian or human tumors which comprises administering to said mammals or humans an effective tumor inhibiting amount of a compound according to claim 1, in pharmaceutically acceptable form.
8. A method according to claim 7 wherein the tumor is a leukemia tumor.
9. A method according to claim 7 wherein the tumor is a tumor type treatable with BCNU or MeCCNU.
EP19810902234 1980-08-14 1981-08-14 5,6-o-isoalkylidene ascorbic acid derivatives. Withdrawn EP0057699A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17794080A 1980-08-14 1980-08-14
US177940 1980-08-14

Publications (2)

Publication Number Publication Date
EP0057699A1 true EP0057699A1 (en) 1982-08-18
EP0057699A4 EP0057699A4 (en) 1982-11-08

Family

ID=22650546

Family Applications (2)

Application Number Title Priority Date Filing Date
EP19810902234 Withdrawn EP0057699A4 (en) 1980-08-14 1981-08-14 5,6-o-isoalkylidene ascorbic acid derivatives.
EP19810902235 Ceased EP0057700A4 (en) 1980-08-14 1981-08-14 Nitrosourea derivatives having antitumour activity and pharmaceutical compositions containing the same.

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP19810902235 Ceased EP0057700A4 (en) 1980-08-14 1981-08-14 Nitrosourea derivatives having antitumour activity and pharmaceutical compositions containing the same.

Country Status (6)

Country Link
EP (2) EP0057699A4 (en)
JP (2) JPS57501580A (en)
DK (2) DK167282A (en)
HU (1) HU185969B (en)
NO (2) NO821221L (en)
WO (2) WO1982000642A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60130582A (en) * 1983-12-19 1985-07-12 Takeda Chem Ind Ltd Antioxidant for food, ascorbic acid derivative and its production
JPS60139619A (en) * 1983-12-27 1985-07-24 Mutsuyuki Kochi Antitumor agent comprising o-bnezylidene-ascorbic acid or its salt
US5405412A (en) * 1994-04-13 1995-04-11 The Procter & Gamble Company Bleaching compounds comprising N-acyl caprolactam and alkanoyloxybenzene sulfonate bleach activators

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2539483A (en) * 1945-03-28 1951-01-30 Simon L Ruskin Urea ascorbate and complexes containing the same and process for their manufacture
US3074998A (en) * 1959-12-10 1963-01-22 Shell Oil Co Enol carbamates
CH495980A (en) * 1967-02-25 1970-09-15 Bayer Ag Process for the preparation of benzodioxane-N-methylcarbamates
DE2346305A1 (en) * 1973-09-14 1975-04-03 Basf Ag NEW CARBAMATES AND THEIR USE AS A MEDICINAL PRODUCT
US4111958A (en) * 1977-06-03 1978-09-05 Pfizer Inc. Ascorbic acid synthesis
US4148921A (en) * 1977-07-13 1979-04-10 Suami T Antitumor agents
NL7904249A (en) * 1978-06-20 1979-12-27 Cancer Res Nat Found NEW CYCLIC ACETALS WITH CYTOSTATIC, BLOOD PRESSURE REDUCING AND PAIN-ANTI-PAIN ACTIONS, METHOD OF PREPARING THESE COMPOUNDS AND PHARMACEUTICAL PREPARATIONS CONTAINING SUCH COMPOUND.
JPS554324A (en) * 1978-06-26 1980-01-12 Kaken Pharmaceut Co Ltd Novel glycopyranosidoamine derivative, its preparation, and antitumor agent comprising it as active constituent
JP2811964B2 (en) * 1990-12-20 1998-10-15 富士通株式会社 Connection partner designation method

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO8200644A1 *

Also Published As

Publication number Publication date
NO821220L (en) 1982-04-14
HU185969B (en) 1985-04-28
JPS57501581A (en) 1982-09-02
JPS57501580A (en) 1982-09-02
WO1982000642A1 (en) 1982-03-04
EP0057700A4 (en) 1982-11-17
NO821221L (en) 1982-04-14
EP0057699A4 (en) 1982-11-08
EP0057700A1 (en) 1982-08-18
DK167182A (en) 1982-04-14
DK167282A (en) 1982-04-14
WO1982000644A1 (en) 1982-03-04

Similar Documents

Publication Publication Date Title
KR100308463B1 (en) Stilbene derivatives and anticancer agents containing them
KR100208315B1 (en) 9-substituted-8-unsubstituted-9-deazaguanines
US4636508A (en) 5-pyrimidinecarboxyamides and treatment of leukemia therewith
EP0057699A1 (en) 5,6-o-isoalkylidene ascorbic acid derivatives
EP0046713B1 (en) Fluorinated pentene diamine derivatives
US4423236A (en) 5,6,-0-Isoalkylidene ascorbic acid derivatives
KR950001040B1 (en) Thiourea derivatives and anti-microbial agent and antiulcer agent containing the same
JPS6220183B2 (en)
EP0229658B1 (en) Fluorinated diaminoalkyne derivatives
US4130648A (en) 5-Fluorouracil derivatives and antitumor preparations containing the same
EP0041792A1 (en) Platinum compounds having antitumor or antimicrobial activity, and pharmaceutical preparations containing them
US4250180A (en) Method of treating arrhythmia
US4421768A (en) Fluorinated diamino-heptene and-heptyne derivatives
US4686215A (en) Pharmaceutical composition and method for treating tumors susceptible to 2-carbamoylaziridine
CA1179372A (en) 1-branched-alkyl-3-(2-haloethy)-3-nitrosoureas as novel antitumor agents
EP0072762B1 (en) Fluorinated diaminoalkene derivatives
EP0378706B1 (en) 5-substituted uridine derivatives and intermediates for their preparation
US4820706A (en) Pteridine derivatives and method of treating leukemia employing same
GB2023595A (en) Nitrosourea compounds process for their preparation and compositions containing them
US4423073A (en) Fluorinated diaminopentene derivatives
EP0072760B1 (en) Fluorinated diamino-heptene and -heptyne derivatives
EP0172059B1 (en) Derivatives of oxaazaphosphorine, process for their preparation and pharmaceutical compositions containing them
EP0412015B1 (en) Derivatives N-(vincristinyl-23) and N-(noranhydro-5-vinblastinyl-23) of amino-1 methylphosphonic acid, their process of preparation and pharmaceutical compositions containing them
EP0213526A1 (en) Spergualin-related compounds, a process for their preparation and their use as medicaments
US4939156A (en) New tetramethyl-cis-diaza-bicyclo{4.2.0}octane-3,5-dione derivatives having differentiation-inducing activity and antiviral activity

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19820419

AK Designated contracting states

Designated state(s): AT CH DE FR GB LI LU NL SE

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NATIONAL FOUNDATION FOR CANCER RESEARCH, INC.

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19850124

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WELEBIR, ANDREW